Innovative precision medicine for the treatment of complement-related conditions and oncology
Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company with a development product pipeline that includes a complement Factor B inhibitor (NXP100) for the treatment of diseases caused by dysregulated activity of the complement system, and two kinase inhibitors for the treatment of advanced cancers (NXP900, a SRC/YES1 inhibitor, and NXP200, a paradox breaker BRAF inhibitor).
Latest Press Releases
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
- Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
- Nuvectis Pharma To Participate in Upcoming Investor Conferences
- Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
- Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Stock Information
Nuvectis Pharma, Inc.
NVCT
Latest Presentation
Explore our latest investor presentation for insights into our strategy, performance, and future growth opportunities.